中国医院用药评价与分析2025，Vol.25Issue(3)：317-318,324,3.DOI:10.14009/j.issn.1672-2124.2025.03.014
钠-葡萄糖共转运蛋白2抑制剂在肾移植受者中的应用
Application of Sodium-Glucose Cotransporter 2 Inhibitor in Kidney Transplant Recipients
摘要
Abstract
OBJECTIVE:To probe into the efficacy and safety of application of sodium-glucose cotransporter 2 inhibitors(SGLT2i)in renal transplant recipients.METHODS:Kidney transplant recipients who were given SGLT2i and regularly followed up for more than 1 year in the hospital from Jan.2020 to Jan.2023 were retrospectively analyzed,and a total of 21 patients were enrolled.The basic information(gender,age,height and weight)of kidney transplant recipients,clinical data of laboratory test indicators(glycosylated hemoglobin,creatinine,serum sodium,serum potassium,total cholesterol,triacylglycerol,high-density lipoprotein cholesterol and low-density lipoprotein cholesterol)and adverse drug reactions before SGLT2i treatment and after 1,6 and 12 months of treatment were collected.RESULTS:Of the 21 recipients enrolled in the study,12 cases(57.14%)had a previous diagnosis of type 2 diabetes,the average time was(1.75±1.83)years from kidney transplant to initiation of SGLT2i therapy,and the average duration of SGLT2i therapy was(19.69±9.80)months.Compared with before SGLT2i treatment,glycosylated hemoglobin decreased after 6 months of treatment,blood sodium after 12 months of treatment and blood potassium after 1 month of treatment increased,with statistically significant differences(P<0.05),the differences in renal function,blood sodium,blood potassium and blood lipids at the other time periods after treatment were not statistically significant compared with those before SGLT2i treatment(P>0.05).During treatment,the incidence of urinary tract infection was 19.05%(4/21).CONCLUSIONS:SGLT2i can reduce the glycosylated hemoglobin level of renal transplant recipients and is generally well tolerated by patients,but vigilant is needed for urinary tract infection and genital fungal infection.关键词
钠-葡萄糖共转运蛋白2抑制剂/肾移植/移植后糖尿病Key words
Sodium-glucose cotransporter 2 inhibitor/Kidney transplant/Post-transplant diabetes mellitus分类
医药卫生引用本文复制引用
张雅鑫,刘媛媛,张维,谢吉科,唐婧..钠-葡萄糖共转运蛋白2抑制剂在肾移植受者中的应用[J].中国医院用药评价与分析,2025,25(3):317-318,324,3.基金项目
北京慢性病防治与健康教育研究会糖尿病防治及管理研究专项科研课题(No.MBZX0092024012) （No.MBZX0092024012）
